PDGF signaling in pulmonary arterial hypertension
Open Access
- 1 October 2005
- journal article
- editorial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 115 (10), 2691-2694
- https://doi.org/10.1172/jci26593
Abstract
The pathobiology of pulmonary arterial hypertension (PAH) includes endothelial cell dysfunction and proliferation and migration of VSMCs. As PDGF has been implicated in these processes, Schermuly et al. hypothesized that altered PDGF signaling may be involved in the vascular remodeling observed in PAH. To explore this notion further, the authors evaluated the effects of the PDGF receptor inhibitor STI571 in 2 different animal models of pulmonary hypertension. In both models, after development of pulmonary vascular disease, administration of STI571 reversed pulmonary vascular changes. These studies provide preclinical proof of concept for the clinical development of a PDGF inhibitor as a targeted therapy for PAH patients.This publication has 20 references indexed in Scilit:
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2005
- Reversal of experimental pulmonary hypertension by PDGF inhibitionJCI Insight, 2005
- Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary HypertensionCirculation, 2005
- Treatment of Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2004
- Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertensionThorax, 2004
- Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetusAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2003
- Hypoxic Activation of Adventitial Fibroblasts*Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2002
- Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitorNature Medicine, 2000
- Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular diseaseJCI Insight, 2000
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionThe New England Journal of Medicine, 1996